Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DARMEC

Financiado

Cerrado

Drug adverse reactions predictability exploring the mechanisms underlying the u...

Drug adverse reactions predictability exploring the mechanisms underlying the unexplained interindividual differences in drug metabolism and transport Drug treatment is often inefficient. Only 30–60% of patients respond properly to treatment with e.g. antidepressants, beta-blockers, statins and antipsychotics. Furthermore, adverse drug reactions (ADRs) frequently occur and caus... ver más

31/10/2016

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

INTERDRUG Epigenetic mechanisms underlying inter individual difference... 206K€ Cerrado

PSY-PGx A New Intervention for Implementation of Pharmacogenetics in... 8M€ Cerrado

FIGHTINGDRUGFAILURE Priorities and Standards in Pharmacogenomic Research Opport... 3M€ Cerrado

PGXOME A pharmacogenomic exploration of adverse drug reactions in e... 83K€ Cerrado

M-DrivE Metabolic Drivers of Epigenetic Modifications metabolic ind... 157K€ Cerrado

PharmGenHUB Pharmacogenomics Hub in a strengthened IMGGE 1M€ Cerrado

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Drug treatment is often inefficient. Only 30–60% of patients respond properly to treatment with e.g. antidepressants, beta-blockers, statins and antipsychotics. Furthermore, adverse drug reactions (ADRs) frequently occur and cause about 7% of all hospital admissions, a frequency that is increased to 30% in elderly subjects above 70 years of age. This is due to a great extent to pharmacokinetics differences. Epigenetic modifications have been demonstrated to potentially participate in the regulation of ~60 human ADME genes. A correlation between the gene’s epigenetic state and possible influence on drug therapy outcome has been experimentally established only in relation to a few ADME genes. Several drugs with epigenetic actions are currently used or on clinical trials. The best examples are DNA Methyltransferases (DNMTs) and Histone Deacetylase (HDACs) inhibitors. In this project, we propose to elucidate the substantial unexplained fraction of interindividual variability in drug response and metabolism using a 3D multi-cell in vitro model of human liver in comparison to transcriptome and phenotype data obtained from a bank of 130 human livers with the following AIMS: AIM1: to unmask the epigenetically regulated ADME genes AIM2: to evaluate the epigenetically regulated ADME genes as interindividual variability biomarkers A list of epimarks of interindividual variation of drug ADME processes will be generated. AIM3: to test the epigenetic influence of candidate drugs. Our objective is to identify the specific ADME genes epigenetically altered by each drug treatment and elucidate the possibilities of interindividual variation in the ADME processes for each of the tested drugs. This approach is extensively multidisciplinary and multisectorial. The experimental design includes tissue bioengineering techniques to develop liver organotypic cultures, drug metabolism functional profiling, and molecular biology approaches, from the perspective of cutting-edge technology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores